• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lexaria Bioscience Corp WT (NQ: LEXXW )

    1.300 +0.110 (+9.24%)
    Streaming Delayed Price Updated: 9:48 AM EDT, Jul 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 420
    Open 1.300
    Bid (Size) 0.9050 (2)
    Ask (Size) 1.200 (10)
    Prev. Close 1.190
    Today's Range 1.300 - 1.300
    52wk Range 0.0500 - 2.500
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
    Via ACCESSWIRE

    Performance

    YTD
    +160.00%
    +160.00%
    1 Month
    +61.23%
    +61.23%
    3 Month
    +73.33%
    +73.33%
    6 Month
    +129.44%
    +129.44%
    1 Year
    +415.87%
    +415.87%

    More News

    Read More
    Lexaria Preparing For Strategic Growth
    Via ACCESSWIRE
    Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
    Via ACCESSWIRE
    Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
    Via ACCESSWIRE
    Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
    Via ACCESSWIRE
    Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study
    Via ACCESSWIRE
    Lexaria Awards Contract For Third GLP-1 Human Pilot Study
    Via ACCESSWIRE
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
    Via ACCESSWIRE
    Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study
    Via ACCESSWIRE
    Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
    Via ACCESSWIRE
    Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
    Via ACCESSWIRE
    Lexaria Awarded New Patents
    Via ACCESSWIRE
    Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
    Via ACCESSWIRE
    Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
    Via ACCESSWIRE
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
    Via ACCESSWIRE
    Lexaria Awards Contract For Next GLP-1 Human Pilot Study
    Via ACCESSWIRE
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
    Via ACCESSWIRE
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
    Via ACCESSWIRE
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.